PDCD1 and hepatocellular carcinoma: Qin et al. (2020) found that camrelizumab could yield an objective response rate (ORR) of 14.7% and a 6-month OS rate of 74.4% in 217 HCC patients. This finding indicates that camrelizumab could achieve clinical efficacy comparable to that of similar PD-1 inhibitors. Thus, camrelizumab became the first PD-1 inhibitor approved in China for the treatment of intermediate and advanced HCC. In addition, the most significant advantage of camrelizumab for Chinese patients is its relatively low price, hence its wide use in China (Chen et al., 2020).